# OnCo record crizotinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/crizotinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "crizotinib" ;
  schema:name "Crizotinib"@en ;
  schema:description "Crizotinib was the first ALK inhibitor, approved four years after ALK fusions were found in lung cancer; it was also the first drug for ROS1 lung cancer and for ALK-positive lymphoma and inflammatory myofibroblastic tumour in children."@en ;
  schema:url <https://onco.cc/drugs/crizotinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Crizotinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5186964> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1408440>, <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=crizotinib>, <https://www.nice.org.uk/guidance/ta1021> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule ALK/ROS1/MET TKI (first generation)" ;
  schema:alternateName "Xalkori" ;
  onco:approval "US 2011: ALK-positive metastatic NSCLC", "US 2016: ROS1-positive metastatic NSCLC", "US 2021: Relapsed ALK-positive ALCL in patients 1-21 years", "US 2022: ALK-positive inflammatory myofibroblastic tumour", "EU 2012: Conditional Oct 2012; full approval 2015", "England (NICE) 2024: ROS1-positive advanced non-small-cell lung cancer in patients who have not had a ROS1 inhibitor" ;
  onco:acceleratedApproval "US 2011-08-26: Locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test" ;
  onco:acceleratedApprovalConfirmed "US 2013-11-20: Locally advanced or metastatic NSCLC that is ALK-positive as detected by an FDA-approved test" ;
  onco:related <https://onco.cc/biomarkers/alk-fusion/>, <https://onco.cc/biomarkers/ros1-fusion/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/alk-positive-nsclc/>, <https://onco.cc/cancers/ros1-positive-nsclc/>, <https://onco.cc/cancers/met-altered-nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/oncogene-addiction/> ;
  onco:trials <https://onco.cc/trials/nct02767804/>, <https://onco.cc/trials/nct06564324/>, <https://onco.cc/trials/nct05987332/>, <https://onco.cc/trials/nct03947385/>, <https://onco.cc/trials/nct04603807/>, <https://onco.cc/trials/nct06140836/>, <https://onco.cc/trials/profile-1014/>, <https://onco.cc/trials/profile-1001-ros1/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-solomon-n-engl-j-med/> .